GB-Liverpool: GLP Toxicology evaluation of Long-Acting Injectable (LAI) products for LTBI prevention and HCV cure

Descriptions

The University of Liverpool, through its LONGEVITY project funded by Unitaid, is implementing product development and commercialization of Long-Acting Injectable (LAI) formulations for malaria and tuberculosis prevention, and a hepatitis C virus cure for Low- and Middle-Income Countries (LMIC's). The University of Liverpool was awarded 32 million US dollars in early 2020 from Unitaid (https://unitaid.org/) as part of the 40 million US dollar project to fund these activities to commercialisation.https://unitaid.org/news-blog/unitaid-invests-in-long-acting-medicines-to-simplify-treatment-and-prevention-for-hiv-tb-malaria-and-hcv/#en https://www.liverpool.ac.uk/chemistry/news/articles/24m-boost-for-revolutionary-long-acting-medicine-research/ The TB and HCV products are reaching the end of proof-of-concept studies and the University of Liverpool is seeking quotations for provision of GLP toxicology services to support product clinical stage progress. Full outline of study requirements available from the University of Liverpool's tendering website (details included in other information section below)